Competing interests: The BMJ has judged that there are no disqualifying financial ties to commercial companies. The authors declare the following other interests: Bruce H.R. Wolffenbuttel: Consultation for Novo Nordisk on GLP1 scientific data and results, and involved in a Novo Nordisk Post-marketing surveillance study on semaglutide use in type 2 diabetes. Speaker honorarium from Springer MedNet, for a presentation on new insight into genetics and genomics in diabetes diagnosis and treatment. Scientific adviser for a healthcare start-up, Nuevo Care, initiating a dedicated clinic for individuals with B12 deficiency. Scientific adviser for a digital health start-up, Ancora Health, offering preventive health programmes. Member of the Post-Graduate Education Committee of the European Association for the Study of Diabetes. Coordinator/organiser for Post-Graduate Educations and Webinars, Diabetes (Alpha Omega Congress) & Endocrinology (BIG5 Endocrinology course). Member of the editorial board of the Journal of Diabetes and Current Topics in Diabetes. P Julian Owen: none. Mary Ward: Principal investigator on investigating the effect of riboflavin on markers of vascular health in adults with a genetic predisposition to hypertension, supported by Dutch State Mining (DSM)—Health and Biosciences division. We (Ulster University) have been awarded a patent for the treatment of hypertension with Riboflavin. EP2139488A1 USE OF RIBOFLAVIN IN THE TREATMENT OF HYPERTENSION; an intellectual Property License Agreement was signed with DSM, which provides exclusive use of pharmaceutical claims under patent rights in China, Mexico, Japan, Canada, and Europe. Ralph Green: none.